Evotec AG has announced that CHDI Foundation, Inc. has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec.

The collaboration was initiated in 2006 and has grown considerably over this period to fully utilise Evotec's best-in-class integrated neuroscience platform. The extension of this collaboration is a further validation of Evotec's investment in new technologies and capabilities in support of driving innovative drug discovery collaborations. Evotec provides CHDI with a full range of research activities and expertise in the neuroscience area, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics, proteomics and protein production.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are delighted to sign this five-year extension with CHDI. Both parties have developed a tremendous relationship based on progressing excellent science to develop effective treatments for Huntington's disease. We are proud to be part of this global initiative led by the great team at CHDI."

"CHDI's collaboration with our colleagues at Evotec represents one of our largest and longest-standing relationships", saidRobi Blumenstein, President of CHDI Management, Inc. "Over the next five years, we look forward to continuing this collaboration with an important strategic partner in our drive to develop therapeutics that substantially improve the lives of Huntington's disease families."